Review of pharmacotherapy options for the management of obesity

Journal of the American Association of Nurse Practitioners

Volumn 28, Issue 2, 2016, Pages 107-115

  Bragg, Rebecca ^a   Crannage, Erica ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Obesity; Pharmacotherapy; Weight management; Weight regulation

Indexed keywords

AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; FRUCTOSE; LACTONE; LIRAGLUTIDE; LORCASERIN; NALTREXONE; PHENTERMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ANALOGS AND DERIVATIVES; DISEASE MANAGEMENT; HUMAN; OBESITY; UNITED STATES;

BENZAZEPINES; BUPROPION; DISEASE MANAGEMENT; FRUCTOSE; HUMANS; LACTONES; LIRAGLUTIDE; NALTREXONE; OBESITY; PHENTERMINE; UNITED STATES;

EID: 84956825083     PISSN: 23276886     EISSN: 23276924     Source Type: Journal    
DOI: 10.1002/2327-6924.12279     Document Type: Article

References (37)

1. Allison, D. B., Gadde, K. M., Garvey, T. W., Peterson, C. A., Schwiers, M. L., Najarian, T., Day, W. W. (2011). Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity, 20, 330-342. doi:10.1038/oby.2011.330
2. American Medical Association (AMA). (2013). AMA adopts new policies on second day of voting at Annual Meeting [Press release]. Retrieved from http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page
3. Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Still, C. D. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guidelines. Journal of Clinical Endocrinology and Metabolism, 100, 342-262. doi:10.1210/jc.2014-3415
4. Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Dunayevich, E. (2013). A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity, 21, 935-943. doi:10.1002/oby.20309
5. Derosa, G., Cicero, A. F. C., D'Angel, A., Fogari, E., & Maffioli, P. (2012). Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 37, 187-195. doi:10.1111/j.1365-2710.2011.01280.x
6. Eisai. (2012). Belviq (loraserin HCl): Prescribing information. Retrieved from https://www.belviqhcp.com/media/1001/belviq_prescribing_information.pdf.
7. Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011). A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. Journal of Clinical Endocrinology and Metabolism, 92, 3067-3077. doi:10.1210/jc.2011-1256
8. Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. (2009). Annual medical spending attributable to obesity: Payer-and service-specific estimates. Health Affairs, 28, w822-w831. doi:10.1377/hlthaff.28.5.w822
9. Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, G. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomized, placebo-controlled, phase 3 trial. Lancet, 377, 1341-1352. doi:10.1016/S20140-6736(11)60205-5
10. Garvey, W. T., Ryan, D. H., Bohannon, M. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014). Weight-loss therapy in type 2 diabetes: Effects of phentermine and topiramate extended release. Diabetes Care, 37, 3309-3316. doi:10.2337/dc14-0930
11. Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Bowden, C. H. (2012). Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. American Journal of Clinical Nutrition, 95, 297-308. doi:10.3945/ajcn.111.024927
12. Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Dunayevic, E. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A muticentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 376, 595-605. doi:10.1016/S0140-6736(10)60888-4
13. Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Fujioka, K. (2013). Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care, 36, 4022-4029. doi: 10.2337/dc13-0234
14. James, W. P. T. (2008). WHO recognition of the global obesity epidemic. International Journal of Obesity, 32, S120-S126. doi:10.1038/ijo.2008.247
15. Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Yanovski, S. Z. (2014). 2013 AHA/ACC/TOS guidelines for the management of overweight and obesity in adults. Circulation, 129, S102-S138. doi:10.1161/01.cir.0000437739.71477.ee
16. Kelley, D. E., Bray, G. A., Xavier PI-Sunyer, F., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002). Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care, 25, 1033-1041.
17. Novo Nordisk. (2013). Victoza (liraglutide rDNA origin injection): Prescribing information. Retrieved from http://www.novo-pi.com/victoza.pdf
18. Novo Nordisk. (2015). Saxenda(liraglutide rDNA origin injection): Prescribing information. Retrieved from http://www.saxenda.com/
19. Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2012). Prevalence of childhood and adult obesity in the United States, 2011-2012. Journal of the American Medical Association, 311, 806-814. doi:10.1001/jama.2014.732
20. O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Shanahan, W. R. (2012). Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity, 20, 1426-1436. doi:10.1038/oby.2012.66
21. Roche. (2012). Xenical (orlistat): Prescribing information. Retrieved from http://www.xenical.com/xenical/hcp-3_productinfo.do
22. Skolnik, N., & Ryan, D. (2014). Pathophysiology, epidemiology, and assessment of obesity in adults. Journal of Family Practice, 63, S3-S10.
23. Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Shanahan, W. R. (2010). Multicenter, placebo-controlled trial of lorcaserin for weight management (BLOOM). New England Journal of Medicine, 363, 245-256. doi:10.1056/NEJMoa0909809
24. Sturm, R., & Hattori, A. (2013). Morbid obesity rates continue to rise rapidly in the United States. International Journal of Obesity, 37, 889-891. doi:10.1038/ijo.2012.159
25. Takeda Pharmaceuticals America. (2014). Contrave (naltrexone HCl and bupropion HCl extended-release): Prescribing information. Retrieved from http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&CountryCode=US&LanguageCode=EN&cacheRandomizer=0653f325-ce71-4384-9b9f-16144373e9da
26. Torgerson, J. S., Hauptman, J., Boldrin, M., & Sjostrom, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 27, 155-161.
27. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS). (2011, November). Decision memo for behavioral therapy for obesity (CAG-00423N). Retrieved from http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?&NcaName=Intensive%20Behavioral%20Therapy%20for%20Obesity&bc=ACAAAAAAIAAA&NCAId=253&
28. U.S. Department of Health and Human Services, Food and Drug Administration (FDA). (2007). FPL for approval of NDA 21-887. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021887s000ltr.pdf
29. U.S. Department of Health and Human Services, National Institutes of Medicine National Heart, Lung, and Blood Institute. (1998). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults (NIH Publication Number 98-4083). Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK2003/
30. U.S. Department of Health and Human Services, National Institutes of Medicine National Heart, Lung, and Blood Institute. (2000). The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults (NIH Publication Number 00-4084). Retrieved from http://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf
31. U.S. Food and Drug Administration (FDA). (2014). FDA Briefing Document NDA 206321 Liraglutide Injection, 3 mg. Retrieved from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM413317.pdf
32. Vivus. (2014). Qysemia (phentermine and topiramate extended-release): Prescribing information. Retrieved from https://www.belviqhcp.com/media/1001/belviq_prescribing_information.pdf
33. Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Dunayevich, E. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity, 19, 110-120. doi:10.1038/oby.2010.147
34. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE maintenance randomized study. International Journal of Obesity, 37, 1443-1451. doi:10.1038/ijo.2013.120
35. Wadden, T. A., West, D. S., Neiberg, R. H., Wing, R. E., Ryan, D. H., Johnson, K. C., Vitolins, M. (2009). One year weight losses in the Look AHEAD study; factors associated with success. Obesity, 17, 713-722. doi:10.1038/oby.2008.637
36. Weissman, N. J., Sanchez, M., Koch, G. G., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2013). Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circulation: Cardiovascular Imaging, 6, 560-567. doi:10.1161/CIRCIMAGING.112.000128
37. Zhou, Y. H., Ma, X. Q., Wu, C., Lu, C., Zhang, S. S., Guo, J., He, J. (2012). Effect of anti-obesity drug on cardiovascular risk factors: A systematic review and meta-analysis of randomized controlled trials. PLoS One, 7, e39062. doi:10.1377/journal.pone.0039062